Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents
- 1 April 2002
- journal article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 46 (4), 495-504
- https://doi.org/10.1067/mjd.2002.122187
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- The eczema area and severity index (EASI): assessment of reliability in atopic dermatitisExperimental Dermatology, 2001
- The prevalence of atopic dermatitis in Oregon schoolchildrenJournal of the American Academy of Dermatology, 2000
- Atopic dermatitis: New insights and opportunities for therapeutic interventionJournal of Allergy and Clinical Immunology, 2000
- Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapyBritish Journal of Dermatology, 2000
- A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacologyBritish Journal of Dermatology, 1999
- Disease Management of Atopic Dermatitis: a Practice ParameterAnnals of Allergy, Asthma & Immunology, 1997
- A Short-Term Trial of Tacrolimus Ointment for Atopic DermatitisNew England Journal of Medicine, 1997
- In vivo expression of IL-12 and IL-13 in atopic dermatitisJournal of Allergy and Clinical Immunology, 1996
- The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validationBritish Journal of Dermatology, 1994
- High Frequency of IL-4–Producing CD4+ Allergen-Specific T Lymphocytes in Atopic Dermatitis Lesional SkinJournal of Investigative Dermatology, 1991